Status:
COMPLETED
Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
To quantify the incremental cost of infections in patients treated with etanercept, adalimumab or infliximab versus abatacept.
Eligibility Criteria
Inclusion
- 18 years of age and older;
- Have a diagnosis of of rheumatoid arthritis (ICD-9:714x.xx);
- Have been enrolled for at least 6 months for the 6 months assessment and 12 months for the 12 months assessment;
- are enrolled in a health plan between February 2006 and June 2009
- have claims indicating at least one use of either abatacept, etanercept, adalimumab or infliximab for at least 6 months for teh 6 months assessment and 12 months for the 12 months assessment
Exclusion
- Patients not continuously eligible for health plan benefits for the same evaluation periods will be excluded
- Patients who are on other biologics in the 6 and 12 month post-index period will be excluded (ex. those in the abatacept cohort will be excluded if they also have claims for etanercept in the 6 and 12 month post-index period).
- Patients on biologics 6 months prior to the biologic index date will also be excluded
- Patients with diagnosis for other non-RA conditions commonly treated with biologics (ex. Crohn's disease) during the 6 month pre-index period.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT01166620
Start Date
June 1 2010
End Date
March 1 2012
Last Update
April 13 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.